CCK receptor Inhibitors
Cholecystokinin (CCK) is a peptide hormone and neurotransmitter that plays a vital role in the regulation of the gastrointestinal (GI) and central nervous systems. It is secreted by I-cells in the duodenum and jejunum in response to the presence of fats and proteins, and it is also widely distributed throughout the brain. CCK exerts its biological effects through two distinct G-protein coupled receptors: CCK1 and CCK2. CCK1 receptors are primarily located in the periphery, including the gallbladder, pancreas, and vagus nerve, where they mediate gallbladder contraction, pancreatic enzyme secretion, and the induction of satiety. CCK2 receptors are the predominant subtype in the central nervous system and the gastric mucosa, where they regulate anxiety, memory, and the secretion of gastric acid. Dysregulation of the CCK system is implicated in several pathological conditions, including GI motility disorders, panic and anxiety disorders, and certain types of cancer, such as pancreatic and gastric tumors, where CCK can act as a growth factor.
The development of CCK receptor inhibitors has targeted both subtypes for different therapeutic indications. CCK1 receptor antagonists, such as Devazepide and Loxiglumide, have been investigated for the treatment of irritable bowel syndrome, chronic constipation, and acute pancreatitis. While these compounds showed promise in preclinical models by modulating GI transit and reducing pain, their clinical success has been limited by modest efficacy in large-scale human trials. On the other hand, CCK2 receptor antagonists have been pursued primarily for their potential as anxiolytic and anti-panic agents, as well as for treating peptic ulcers and gastrinomas. Proglumide, a non-selective CCK antagonist, was one of the first drugs in this class and has been used to treat gastric ulcers, though it is relatively weak. More potent and selective CCK2 antagonists, such as Gastrazole and Netazepide, are being evaluated for their ability to inhibit the trophic effects of gastrin on tumor cells and for managing hypergastrinemia.
Current research progress also highlights the potential of CCK inhibitors in pain management. CCK is known to act as an anti-opioid peptide; thus, CCK antagonists may enhance the analgesic effects of opioids and prevent the development of opioid tolerance. This has led to the exploration of combination therapies involving CCK2 antagonists and morphine. Inhibitors are generally classified by their receptor selectivity and their chemical nature. One of the key challenges in this field is the high degree of homology between the two receptor subtypes, making the design of highly selective inhibitors difficult. The development of radiolabeled CCK receptor antagonists for PET imaging is an exciting advancement, allowing for the non-invasive visualization of CCK2 receptor-positive tumors and helping to guide personalized treatment strategies.
As research continues, the focus is shifting toward the use of CCK receptor imaging for cancer diagnosis and the development of biased agonists or antagonists that can selectively modulate specific signaling pathways downstream of the receptors.
